Category: Regulations
-
New Type of Antibiotic Set for Early Trial
A clinical trial is set to test a type of drug that its developers say is designed to treat infections from bacteria resistant to earlier antibiotics.
-
Trial to Explore Microbiome Therapy for Hypertension
A clinical trial is set to begin that tests live bacteria as a treatment for hypertension, or high blood pressure, a condition affecting 1 in 3 adults in the U.S.
-
Trial Testing Stem-Cell Implant for Cartilage Repair
An early clinical trial testing implants of a person’s stem cells to repair damaged knee cartilage in younger adults returned largely favorable results.
-
Trial to Test Radio Waves to Treat Alzheimer’s
A clinical trial is inviting individuals with Alzheimer’s disease to test a device that its designers claim can reverse cognitive impairment resulting from Alzheimer’s disease.
-
Many Health Apps Found Not Helping People in Need
Many mobile apps designed to help manage one’s health are not assisting people in most need of that help and often do not appropriately respond to information with dangerous consequences.
-
High Leukemia Remissions Reported for Engineered T-Cells
First results from an international clinical trial of engineered immune system cells to treat leukemia in children show high rates of remission, but also many severe adverse effects.
-
Stem Cell Therapy Shows Early Results with Multiple Myeloma
First results from an early clinical trial show some patients with multiple myeloma receiving replacement blood-forming stem cells achieved at least a partial response and did not suffer severe adverse effects.
-
Engineered T-Cell Trial Halted After Participant Dies
A clinical trial testing treatments that modify immune system cells to fight leukemia in adults was stopped after one of the patients died from inflammation in the brain.
-
Targeted Leukemia Drugs Sharply Raising Costs of Care
Drugs directly attacking cancer cell growth show high remission rates with a common form of leukemia, but a new study suggests the high costs of these drugs could impose difficult economic burdens on patients and the health care system.
-
Trial Shows Antibody Reduces Days with Migraines
First results from a late-stage clinical trial shows a synthetic antibody reduces the number of days with migraines per month among people with episodic or infrequent migraines.